Biblio Discovery — Demo Discovery Service

4 results for "Lechner, Marie"

Showing 1–4 · 1.10 seconds · RSS

  1. Journal Article Full text

    tert-Butyl 3-oxo-2-oxa-5-aza­bicyclo­[2.2.1]heptane-5-carboxyl­ate

    Lechner, Marie-Charlotte; Aubert, Emmanuel; Guichard, Gilles et al.

    Acta Crystallogr Sect E Struct Rep Online · 2008 · English · PubMed Central

    The title compound, C(10)H(15)NO(4), also known as N-tert-butyl­oxycarbonyl-allohydr­oxy-l-proline lactone, is quite similar to N-acetyl-allohydr­oxy-l-proline lactone [Lenstra, Petit & Geise (1979 ▶). Cryst. Struct. Commun. 8, 1023–1029], whereby both carbonyl groups point roughly in the same…

  2. Book Full text

    Angles morts du numérique ubiquitaire

    Citton, Yves; Lechner, Marie; Masure, Anthony

    Presses universitaires de Paris Nanterre · 2023 · French · DOAB

    Si le numérique est désormais ubiquitaire, s’il s’infiltre partout - pour nous connecter, nous assister, nous augmenter, nous surveiller - quels sont les angles morts de ce regard dont le centre est partout et la circonférence nulle part ? C’est à cette question qu’essaient de répondre les 145…

  3. Journal Article Full text

    Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels

    Beyrath, Julien; Chekkat, Neila; Smulski, Cristian R. et al.

    Oncotarget · 2016 · English · PubMed Central

    DR4 (Death Receptor 4) and DR5 (Death Receptor 5) are two potential targets for cancer therapy due to their ability to trigger apoptosis of cancer cells, but not normal ones, when activated by their cognate ligand TRAIL (TNF related apoptosis-inducing ligand). Therapies based on soluble recombinant…

  4. Journal Article Full text

    Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes

    Chekkat, Neila; Lombardo, Caterina M.; Seguin, Cendrine et al.

    Oncotarget · 2018 · English · PubMed Central

    Tumor Necrosis Factor Receptor Apoptosis Inducing Ligand (TRAIL) appears as an interesting candidate for targeted cancer therapy as it induces apoptosis in cancer cells without toxicity to normal cells. TRAIL elicits apoptosis through agonist death receptor TRAIL-R1 and TRAIL-R2 engagement…